Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Myeloid and Monocytic Leukemia" returned 9 results:


A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
Principal Investigator(s): Adriana K. Malone

A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone, and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease
Principal Investigator(s): Eileen Scigliano

A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
Principal Investigator(s): Luis M. Isola

A Phase II Controlled Trial of a Single ProHema-CB unit (Ex Vivo CXCR4-Upregulated CD34+ Hematopoietic Progenitor Cells, Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative Conditioning For Patients Age 15-55 Years With Hematologic Malignancies
Principal Investigator(s): Luis M. Isola

A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects with Myelofibrosis
Principal Investigator(s): Ronald Hoffman

Phase I 01910.Na Infusion w/Leukemia or Myelodyspastic MDS
Principal Investigator(s): Lewis R. Silverman

Phase I Dose Escalation Study of ON 01910.Na with Increasing Duration of an Initial 3-Day Continuous Infusion in Patients with Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Principal Investigator(s): Lewis R. Silverman

A Randomized Phase II Trial of Decitabine-Based Induction Strategies for Patients = 60 Years Old With Acute Myeloid Leukemia (AML)
Principal Investigator(s): Celia L. Grosskreutz

A Phase 2, Multi-Center, Open Label, Randomized, Parallel-Group Study of A Lenalidomide (Revlimid) Regimen or A Sequential Azacitidine (Vidaza) plus Lenalidomide (Revlimid) Regimen versus Conventional Care for Therapy of Subjects 65 Years or Older with Newly Diagnosed Acute Myeloid Leukemia
Principal Investigator(s): Lewis R. Silverman